ERCP与急性胰腺炎的临床研究
|
摘要
第一部分内镜联合早期肠内营养治疗急性重症胆源性胰腺炎
目的急性重症胆源性胰腺炎是外科急危重症,并发症多,死亡率高,治疗费用高,效果尚不满意。本研究通过评价内镜联合早期肠内营养治疗的临床效果,以期改善急性重症胆源性胰腺炎的治疗效果,降低并发症及治疗费用。方法对我院2004年1月至2009年7月间收治的105例急性重症胆源性胰腺炎患者,随机分为两组,50例行内镜ERCP+EST+ERBD,同时放置肠内营养管行早期肠内营养；与55例常规治疗联合肠内外营养的患者进行比较。分别对患者术后主观症状、体征、血常规、生化指标、血清内毒素含量、TNF-α、IL-10、CD4+/CD8+、CT分级、患者总住院费用及住院时间等指标进行比较。结果入选患者均可顺利完成两种治疗方案。与传统治疗方案相比,内镜联合早期肠内营养方案对患者主观症状、体征、血常规、生化指标、内毒素血症、TNF-α、IL-10、CD4+/CD8+、CT分级改善明显,患者住院费用、住院时间均明显减少。结论内镜联合早期肠内营养治疗急性重症胆源性胰腺炎是安全、有效、经济的治疗方案。
第二部分ERCP术后胰腺炎技术层面危险因素分析(附7168例报告)
目的：ERCP术后胰腺炎(PEP)是ERCP术后最常见和严重的并发症之一。本研究通过回顾性分析四个发展时期中PEP的发病率和相关危险因素的差异,试图证实ERCP术后胰腺炎发生率逐渐下降可能是归于严格的患者选择标准、内镜设备的完善和技术的改进。方法：回顾性分析了1989年12月至2010年3月于兰州大学第一医院行诊断与治疗性ERCP的7168例次患者的临床资料,根据ERCP设备和技术的不同发展阶段,病例被分成4组。对各组间PEP的发病率和主要危险因素进行比较。结果：7168例ERCP术后胰腺炎的总发生率为3.70%(265/7,168)。比较四个时期PEP的发生率,第一阶段为4.09%(77/1,884)；第二阶段为5.79%(86/1,489)；第三阶段为3.95%(62/1,568)；第四阶段为1.80%(40/2,227)。通过单变量分析,发现胰管内支架置入(OR 0.300)和应用异丙酚复合麻醉(OR 0.632)对于PEP似乎是保护性因素。通过多变量分析,发现重复插管(OR 3.462)、胰管造影(OR 3.218)、胆管括约肌球囊扩张(OR 2.847)、乳头预切开(OR 2.493)、高压非选择性注射(OR 1.428)、过度电凝切开(OR 1.263)、既往胰腺炎病史(OR 3.843)和Oddi括约肌功能紊乱(OR 1.782)是明确引起PEP相关危险因素。结论：PEP发生率的明显降低与不断改善的ERCP操作技术相关。通过持续地改进ERCP技术,例如常规使用导丝、高选择性插管、胰管内支架置入和谨慎的乳头切开,PEP发病风险可以尽可能被降低。
第三部分胆胰管双支架置入术预防高危患者ERCP术后胰腺炎的临床价值
目的：ERCP术后胰腺炎(post-ERCP pancreatitis, PEP)是最常见的和最严重的ERCP术后并发症之一,本研究的目的是评估内镜下胆胰管双支架植置入术对PEP的临床预防效果。方法：收集我院普外二科2005年1月至2011年8月期间经ERCP诊疗中心对行内镜治疗的具有PEP高危因素的患者409例,根据术中是否留置胆管支架及胰管支架分为三组,分布比较各组之间PEP发生率和严重程度的差异。结果：PEP发生率：无支架组23.2%(13/56),ENBD/ERBD组11.9%(32/270), ERBD+ERPD组3.6%(3/83),三组之间均存在显著差异(P<0.05)。三组患者轻度PEP发生率无显著差异；但ERBD+ERPD组中度PEP的发生率较无支架组(1.2% vs.0.10.7%；P=0.017)和ENBD/ERBD组(1.2% vs.7.4%；P=0.035)均显著降低；ENBD/ERBD重度PEP的发生率较无支架组显著降低(1.1%vs.7.1%；P=0.018)。结论：内镜下胆胰管双支架置入术可以降低ERCP术后胰腺炎的发生率和严重程度,对PEP是一项安全、有效的预防措施,值得临床进一步推广应用。
Objective:Acute severe biliary pancreatitis (ASBP) is a severe and fatal disease, and the expenditure is huge and therapeutic effects are still not satisfactory. This study aimed to improve the therapeutic effects and reduce the expenditure of ASBP treatment. Methods:105 patients diagnosed with ASBP were recruited in our department from January 2004 to July 2009. Patients were divided into two groups; the E group:50 patients who underwent endoscopic retrograde choledochopancreatography (ERCP)+endoscopic sphincterotomy (EST)+ endoscopic lithotripsy basket (ESR)+endoscopic retrograde biliary drainage (ERBD) and enteral nutrition (EN), and the R group:55 patients who underwent conventional treatment without ERCP. Subsequently, subjective symptoms, signs, biochemical analysis, serum endotoxin, TNF-α, grades by computed tomography (CT), cost of hospitalization and length of stay were compared between the two groups. Results: All enrolled patients complied well with all therapeutic regimens. Endoscopic therapy that combined EN could significantly improve symptoms, clinical signs, laboratory values, tumor necrosis factor a and endotoxin while significantly reducing hospital expenditure and length of hospital stay. The experimental findings revealed that there were obvious advantages in the E group compared with the R group. Conclusions: Endoscopic therapy combined with EN is an effective, safe and economic therapeutic regimen of acute severe biliary pancreatitis.
Objective:Post-ERCP pancreatitis (PEP) is one of the most common and serious complications after ERCP. This study aims to test this hypothesis that the incidence of post-ERCP declined over time due to improved patient selection and/or endoscope equipments and endoscopic techniques. Methods:A total 7,168 cases of ERCP procedures were retrospectively analyzed. According to different development stages of ERCP equipments and techniques, cases were divided into four groups. Incidence rate and major risk factors for acute PEP were compared between groups. Results:Of the 7,168 cases, the overall incidence of PEP was 3.70%(265/7,168). The incidence of PEP was 4.09%(77/1,884) in the StageⅠ,5.79%(86/1,489) in the StageⅡ,3.95% (62/1,568) in the StageⅢ, and 1.80%(40/2,227) in the StageⅣ. The identifiable risk factors for PEP from multivariate analysis include repeated cannulation (OR 3.462), pancreatic duct injection (OR 3.218), balloon dilation of biliary sphincter (OR 2.847), papillae pre-cut (OR 2.493), non-selective high-pressure injection (OR 1.428), excessive electrocoagulation incision (OR 1.263), history of pancreatitis (OR 3.843), and suspected sphincter of Oddi dysfunction (OR 1.782). Conclusions:Improved technical procedures were associated with a significant reduction in the incidence of PEP. Risks for developing PEP may be minimized by constant improvement in the ERCP techniques, such as a routine use of guidewire, highly selective cannulation, pancreatic stent placement, and cautious incision.
Objective:Post-ERCP pancreatitis (PEP) is one of the most common and serious complications after ERCP. This study aims to assess prophylactic value of pancreatic and biliary stent placement for PEP. Methods:A total 409 high risk cases were divided into three groups according to different therapeutic strategy. Incidence rate and degree of PEP were compared between groups. Results:The incidence of PEP was 23.2%(13/56) in non drainage group,11.9%(32/270) in the group of ENBD/ERBD,3.6%(3/83) in the group of ERBD+ERPD, there were significant difference of incidence of PEP among each group (P<0.05). The incidence of mild PEP was not significantly different among each group (P>0.05). The incidence of moderate PEP in group of ERBD+ERPD was lower than it in group of ENBD/ERBD (1.2% vs.7.4%; P=0.035) and group of non drainage (1.2% vs.0.10.7%; P=0.017). The incidence of severe PEP in group of ENBD/ERBD was lower than it in non drainage group (1.1% vs.7.1%; P=0.018). Conclusions:Pancreatic and biliary stent placement could reduce the incidence and degree of PEP for high risk patients, which is safe and effective approach for prophylaxis of PEP, deserving further clinical application and extension in future.
目的急性重症胆源性胰腺炎是外科急危重症,并发症多,死亡率高,治疗费用高,效果尚不满意。本研究通过评价内镜联合早期肠内营养治疗的临床效果,以期改善急性重症胆源性胰腺炎的治疗效果,降低并发症及治疗费用。方法对我院2004年1月至2009年7月间收治的105例急性重症胆源性胰腺炎患者,随机分为两组,50例行内镜ERCP+EST+ERBD,同时放置肠内营养管行早期肠内营养；与55例常规治疗联合肠内外营养的患者进行比较。分别对患者术后主观症状、体征、血常规、生化指标、血清内毒素含量、TNF-α、IL-10、CD4+/CD8+、CT分级、患者总住院费用及住院时间等指标进行比较。结果入选患者均可顺利完成两种治疗方案。与传统治疗方案相比,内镜联合早期肠内营养方案对患者主观症状、体征、血常规、生化指标、内毒素血症、TNF-α、IL-10、CD4+/CD8+、CT分级改善明显,患者住院费用、住院时间均明显减少。结论内镜联合早期肠内营养治疗急性重症胆源性胰腺炎是安全、有效、经济的治疗方案。
第二部分ERCP术后胰腺炎技术层面危险因素分析(附7168例报告)
目的：ERCP术后胰腺炎(PEP)是ERCP术后最常见和严重的并发症之一。本研究通过回顾性分析四个发展时期中PEP的发病率和相关危险因素的差异,试图证实ERCP术后胰腺炎发生率逐渐下降可能是归于严格的患者选择标准、内镜设备的完善和技术的改进。方法：回顾性分析了1989年12月至2010年3月于兰州大学第一医院行诊断与治疗性ERCP的7168例次患者的临床资料,根据ERCP设备和技术的不同发展阶段,病例被分成4组。对各组间PEP的发病率和主要危险因素进行比较。结果：7168例ERCP术后胰腺炎的总发生率为3.70%(265/7,168)。比较四个时期PEP的发生率,第一阶段为4.09%(77/1,884)；第二阶段为5.79%(86/1,489)；第三阶段为3.95%(62/1,568)；第四阶段为1.80%(40/2,227)。通过单变量分析,发现胰管内支架置入(OR 0.300)和应用异丙酚复合麻醉(OR 0.632)对于PEP似乎是保护性因素。通过多变量分析,发现重复插管(OR 3.462)、胰管造影(OR 3.218)、胆管括约肌球囊扩张(OR 2.847)、乳头预切开(OR 2.493)、高压非选择性注射(OR 1.428)、过度电凝切开(OR 1.263)、既往胰腺炎病史(OR 3.843)和Oddi括约肌功能紊乱(OR 1.782)是明确引起PEP相关危险因素。结论：PEP发生率的明显降低与不断改善的ERCP操作技术相关。通过持续地改进ERCP技术,例如常规使用导丝、高选择性插管、胰管内支架置入和谨慎的乳头切开,PEP发病风险可以尽可能被降低。
第三部分胆胰管双支架置入术预防高危患者ERCP术后胰腺炎的临床价值
目的：ERCP术后胰腺炎(post-ERCP pancreatitis, PEP)是最常见的和最严重的ERCP术后并发症之一,本研究的目的是评估内镜下胆胰管双支架植置入术对PEP的临床预防效果。方法：收集我院普外二科2005年1月至2011年8月期间经ERCP诊疗中心对行内镜治疗的具有PEP高危因素的患者409例,根据术中是否留置胆管支架及胰管支架分为三组,分布比较各组之间PEP发生率和严重程度的差异。结果：PEP发生率：无支架组23.2%(13/56),ENBD/ERBD组11.9%(32/270), ERBD+ERPD组3.6%(3/83),三组之间均存在显著差异(P<0.05)。三组患者轻度PEP发生率无显著差异；但ERBD+ERPD组中度PEP的发生率较无支架组(1.2% vs.0.10.7%；P=0.017)和ENBD/ERBD组(1.2% vs.7.4%；P=0.035)均显著降低；ENBD/ERBD重度PEP的发生率较无支架组显著降低(1.1%vs.7.1%；P=0.018)。结论：内镜下胆胰管双支架置入术可以降低ERCP术后胰腺炎的发生率和严重程度,对PEP是一项安全、有效的预防措施,值得临床进一步推广应用。
Objective:Acute severe biliary pancreatitis (ASBP) is a severe and fatal disease, and the expenditure is huge and therapeutic effects are still not satisfactory. This study aimed to improve the therapeutic effects and reduce the expenditure of ASBP treatment. Methods:105 patients diagnosed with ASBP were recruited in our department from January 2004 to July 2009. Patients were divided into two groups; the E group:50 patients who underwent endoscopic retrograde choledochopancreatography (ERCP)+endoscopic sphincterotomy (EST)+ endoscopic lithotripsy basket (ESR)+endoscopic retrograde biliary drainage (ERBD) and enteral nutrition (EN), and the R group:55 patients who underwent conventional treatment without ERCP. Subsequently, subjective symptoms, signs, biochemical analysis, serum endotoxin, TNF-α, grades by computed tomography (CT), cost of hospitalization and length of stay were compared between the two groups. Results: All enrolled patients complied well with all therapeutic regimens. Endoscopic therapy that combined EN could significantly improve symptoms, clinical signs, laboratory values, tumor necrosis factor a and endotoxin while significantly reducing hospital expenditure and length of hospital stay. The experimental findings revealed that there were obvious advantages in the E group compared with the R group. Conclusions: Endoscopic therapy combined with EN is an effective, safe and economic therapeutic regimen of acute severe biliary pancreatitis.
Objective:Post-ERCP pancreatitis (PEP) is one of the most common and serious complications after ERCP. This study aims to test this hypothesis that the incidence of post-ERCP declined over time due to improved patient selection and/or endoscope equipments and endoscopic techniques. Methods:A total 7,168 cases of ERCP procedures were retrospectively analyzed. According to different development stages of ERCP equipments and techniques, cases were divided into four groups. Incidence rate and major risk factors for acute PEP were compared between groups. Results:Of the 7,168 cases, the overall incidence of PEP was 3.70%(265/7,168). The incidence of PEP was 4.09%(77/1,884) in the StageⅠ,5.79%(86/1,489) in the StageⅡ,3.95% (62/1,568) in the StageⅢ, and 1.80%(40/2,227) in the StageⅣ. The identifiable risk factors for PEP from multivariate analysis include repeated cannulation (OR 3.462), pancreatic duct injection (OR 3.218), balloon dilation of biliary sphincter (OR 2.847), papillae pre-cut (OR 2.493), non-selective high-pressure injection (OR 1.428), excessive electrocoagulation incision (OR 1.263), history of pancreatitis (OR 3.843), and suspected sphincter of Oddi dysfunction (OR 1.782). Conclusions:Improved technical procedures were associated with a significant reduction in the incidence of PEP. Risks for developing PEP may be minimized by constant improvement in the ERCP techniques, such as a routine use of guidewire, highly selective cannulation, pancreatic stent placement, and cautious incision.
Objective:Post-ERCP pancreatitis (PEP) is one of the most common and serious complications after ERCP. This study aims to assess prophylactic value of pancreatic and biliary stent placement for PEP. Methods:A total 409 high risk cases were divided into three groups according to different therapeutic strategy. Incidence rate and degree of PEP were compared between groups. Results:The incidence of PEP was 23.2%(13/56) in non drainage group,11.9%(32/270) in the group of ENBD/ERBD,3.6%(3/83) in the group of ERBD+ERPD, there were significant difference of incidence of PEP among each group (P<0.05). The incidence of mild PEP was not significantly different among each group (P>0.05). The incidence of moderate PEP in group of ERBD+ERPD was lower than it in group of ENBD/ERBD (1.2% vs.7.4%; P=0.035) and group of non drainage (1.2% vs.0.10.7%; P=0.017). The incidence of severe PEP in group of ENBD/ERBD was lower than it in non drainage group (1.1% vs.7.1%; P=0.018). Conclusions:Pancreatic and biliary stent placement could reduce the incidence and degree of PEP for high risk patients, which is safe and effective approach for prophylaxis of PEP, deserving further clinical application and extension in future.
引文
[1]麻树人.ERCP发展历史回顾与应用现状[J].中国消化内镜杂志,2009.26(5)：225-226.
[2]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158.
[3]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[4]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[5]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[6]Gislason H, Horn A, Hoem D, et al. Acute pancreatitis in Bergen, Norway. A study on incidence, etiology and severity. Scand J Surg,2004;93:29-33.
[7]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[8]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志2007；27：441-443
[9]McClave SA, Greene LM, Snider HL, et al. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. JPEN J Parenter Enteral Nutr 1997; 21:14-20
[10]Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol 2006; 20:507-529.
[11]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[12]Freeman ML. DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[13]Christensen M, Matzen P. Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[14]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[15]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[16]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11:222-228.
[17]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656.
[18]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[19]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[20]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[21]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[22]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[23]李汛,朱晓亮,周文策,等.经内镜胰管支架置入在预防ERCP术后胰腺炎高危患者中的临床应用.中国普外基础与临床杂志,2010,17(10)：1006-1009.
[24]潘涛,王一平,杨锦林,等.胰管支架置入术预防内镜逆行胰胆管造影术后胰腺炎的系统评价.中国循证医学杂志,2004,10：693-699.
[25]Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc,2004; 60:544-550.
[26]Angelo Andriulli, Rosario Forlano, Grazia Napolitan, et al. Pancreatic duct stents in the prophylaxis of pancreatic d|IImIge after endoscopic retrograde cholangiopancreatography:a systematic analysis of benefits and associated risks. Digestion,2007,75:156-163.
[27]郝立校,龚彪,别里克.胰管支架预防高危ERCP术后胰腺炎的荟萃分析.中华消化内镜杂志,2010,27(2)：94-98.
[1]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[2]Gislason H, Horn A, Hoem D, et al. Acute pancreatitis in Bergen, Norway. A study on incidence, etiology and severity. Scand J Surg,2004;93:29-33.
[3]张太平,徐徕,赵玉沛.重症急性胰腺炎发病机制.临床外科杂志.2010,18(6)：42]-424.
[4]尹华.内镜治疗胆源性胰腺炎[J].中国中西医结合外科杂志,2007,13(1)：94-96.
[5]Makhija R, Kingsnorth AN.Cytokine storm in acute pancreatitis.J Hepatobiliary Pancreat Surg.2002;9(4):401-10. Review
[6]方金苗,夏时海,李兆申.重症急性胰腺炎发病机制的研究进展.武警医学,2005；16(5)：375-377
[7]张刚,张肇达,刘续宝等.急性胰腺炎大鼠肺内TNF-a基因表达与肺损伤的关系.世界华人消化杂志,2000,8(2)：142
[8]洪亮.急性胰腺炎患者血清CRP、IL-10、TNF-α、NO水平变化及意义.山东医药.2007；47(36)：76-77.
[9]李兆申.胰腺疾病内镜治疗研究进展.中国实用外科杂志,2003；23(1)：31-34.
[10]李兆申.胰腺疾病的内镜治疗进展：急性胰腺炎内镜治疗的价值及安全性.中国实用外科杂志,2005；25(6)：326-328.
[11]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[12]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志,2007；27：441-443.
[13]王文文.血内毒素、D-乳酸、TNF-a在急性胰腺炎发展和转归中的意义.暨南大学硕士学位论文,2011.
[14]中华医学会消化病学分会.肠屏障功能障碍临床诊治建议[J].中华消化杂志,2006,26(9)：620.
[15]寇丽,尤胜义.急性胰腺炎病人T淋巴细胞亚群改变与差异性凋亡.中华肝胆外科杂志.2008,14(8)：569-571
[16]吴阶平,裘法祖.黄家驷外科学.第6版.北京：人民卫生出版社,2005：120-122
[17]都庆国.肠内外营养支持治疗重症急性胰腺炎的临床研究.重庆医科大学硕士论文,2007；03
[18]中华医学会外科学会胰腺学组.急性胰腺炎的临床诊断及分级标准.中华外科杂志1997；35(12)：773-775
[19]邹富胜.急性胆源性胰腺炎的中西医结合治疗.天津医科大学博士学位论文.2006,05
[20]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158
[21]Moon JH, Cho YD, Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis:comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol,2005; 100: 1051-1057
[22]Larkin CJ, Workman A, Wright RE, Tham TC. Radiation doses to patients during ERCP. Gastrointest Endosc,2001; 53:161-164
[23]张姮,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[24]胡冰.规范胆管良性狭窄的内镜治疗.中华消化内镜杂志,2009,26(5)：231-233.
[25]郝俊鸣,李雪梅,佟艳铭,等.胆道蛔虫病的内镜诊断和治疗体会.中国康复理论与实践,2005；11(12)：1044-1045.
[26]沈雪辉,徐美东,姚礼庆,等.内镜治疗胆道蛔虫病的临床价值.中国内镜杂志.2004；10(3)：17-19.
[27]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011；39(2)：381-383.
[28]Sheung-Tat Fan, Edward Lai, Francis Mok, et al. Early treatment of acute biliary pancreatifis by endoscopic papillotomy[J]. N Eng J Med,1993,328:228-232.
[29]罗劲松,张文利,丁顺斌,等.急诊内镜治疗急性胆源性胰腺炎.海南医学,2008；19(9)：42-45.
[30]刘臣海,黄强.内镜治疗51例急性胆源性胰腺炎的临床对比研究.肝胆胰外科杂志,2009；21(1)：56-58.
[31]Cart-Locke DL. Biliary pancreatitis. Can J Gastroenterol,2003; 17(3):205-208.
[32]缪林,范志宁,季国忠,文卫,刘政,黄光明,蒋国斌,吴萍.急性胆源性胰腺炎早期内镜治疗52例.世界华人消化杂志,2004；12：2006-2008.
[33]Jijo V Cherian, Joye Varghese Selvaraj, Rajesh Natrayan and Jayanthi Venkataraman. ERCP in acute pancreatitis. Hepatobiliary Pancreat Dis Int,2007; 6:233-240.
[34]李兆申,许国铭.治疗性ERCP在胰腺疾病中的应用进展.新消化病学杂志,1996；4(5)：277-278
[35]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[36]周鸣清,李能平,陆仁达.急性胆源性胰腺炎的十二指肠镜治疗.中华普通外科杂志2000；15：
[37]王自法,潘承恩,刘绍诰.重症急性胰腺炎发病机理研究进展.中华普通外科杂志1999；14：144-146
[38]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志2007；27：441-443
[39]周文策,张辉,李汛,等.31例内镜联合早期肠内营养治疗急性重症胆源性胰腺炎.世界华人消化杂志,2009；17(16)：1684-1688
[40]Bengmark S. Gut microenvironment and immune function. Curr Opin Clin Nutr Metab Care 1999; 2:83-85
[41]张建松.重症胰腺炎的中西医结合营养支持治疗.北京中医药大学硕士学位论文,2010,05.
[42]Imrie CW, Carter CR, McKay CJ. Enteral and parenteral nutrition in acute pancreatitis. Best Pract Res Clin Gastroenterol 2002; 16:391-397
[43]Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol 2006;20:507-529
[44]Abou-Assi S. Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis:results of a randomized comparative study. Am J Gastroenterol 2002; 97:2255-2262
[45]McClave SA, Snider H, Owens N, Sexton LK. Clinical nutrition in pancreatitis. Dig Dis Sci 1997;42:2035-2044
[46]陈文山,程先能,黄大春.重症急性胰腺炎与免疫应答.检验医学与临床.2009,6(16)：1391-1393.
[47]奚美娟IL.6、IL-10与急性胰腺炎严重程度的相关性研究.苏州大学硕士专业学位论文.2005
[48]陈紫千,汤耀卿.1L-10基因治疗急性胰腺炎的研究现状.国外医学外科学分册,2004,3(1)：74-77
[49]舒国顺.急性胰腺炎早期患者IL-6, TNF, CD4+/CD8+的变化及意义.湖南医学.2000,17(6)：408-410.
[1]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[2]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[3]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[4]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog- raphy. World J Gastroenterol 2007; 13:2655-2668.
[5]Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[6]Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[7]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[8]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[9]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11:222-228.
[10]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656
[11]Lee JK, Park JK, Yoon WJ, et al. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts. J Clin Gastroenterol 2007; 41: 427-431.
[12]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[13]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[14]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc.1991; 37:383-393.
[15]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[16]Pankaj Singh, Ananya Da, Gerard Isenberg, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A metaanalysis of controlled trials. Gastrointest Endosc 2004; 60:544-550.
[17]Akashi R, Kiyozumi T, Tanaka T, et al. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc.2002; 55:50-54.
[18]S. Sherman, T.A. Ruffolo, R.H. Hawes and G.A. Lehman. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology.1991; 101: 1068-1075.
[19]Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media:results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc.1995; 42:312-316.
[20]Baillie J. Predicting and preventing post-ERCP pancreatitis. Curr Gastroenterol Rep.2002; 4:112-119.
[21]Cheung J, Tsoi KK, Quan WL, et al. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis:a systematic review and meta-analysis. Gastrointest Endosc.2009; 70:1211-1219.
[22]Lee TH, Park do H, Park JY, et al. Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. Gastrointest Endosc.2009; 69(3 Pt 1):444-449.
[23]Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc.2004; 59:830-834.
[24]Itoi T, Ishii K, Sofuni A, et al. Single Balloon Enteroscopy-Assisted ERCP Using Rendezvous Technique for Sharp Angulation of Roux-en-Y Limb in a Patient with Bile Duct Stones. Diagn Ther Endosc.2009;2009:154084. Epub 2010 Feb 14.
[25]Martin L Freeman. Prevention of post-ERCP pancreatitis:pharmacologic solution or patient selection and pancreatic stents? Gastroenterology.2003;124(7):1977-1980.
[26]Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction:pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy.2002; 34:280-285.
[27]N Li, A Tieng, S Novak, et al. Effects of Medications on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Pancreatology.2010; 10:238-242
[28]Goulson DT, Fragneto RY. Anesthesia for gastrointestinal endoscopic procedures. Anesthesiol Clin.2009; 27:71-85.
[29]Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation in diagnostic and therapeutic ERCP:propofol is an alternative to midazolam. Endoscopy.2000; 32:233-238.
[30]赵铭宁,杨勇,张文杰,等.ERCP后胰腺炎影响因素分析.肝胆胰外科杂志,2010,22：389-393
[31]潘涛.药物预防ERCP术后胰腺炎的随机对照试验的系统评价.四川大学硕士论文.2004
[1]麻树人.ERCP发展历史回顾与应用现状[J].中国消化内镜杂志,2009.26(5)：225-226.
[2]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[3]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[4]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[5]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[6]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[7]Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[8]Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[9]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[10]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[11]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11: 222-228.
[12]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656
[13]Lee JK, Park JK, Yoon WJ, et al. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts. J Clin Gastroenterol 2007; 41: 427-431.
[14]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[15]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[16]李汛,朱晓亮,周文策,等.经内镜胰管支架置入在预防ERCP术后胰腺炎高危患者中的临床应用.中国普外基础与临床杂志,2010,17(10)：1006-1009.
[17]潘涛,王一平,杨锦林,等.胰管支架置入术预防内镜逆行胰胆管造影术后胰腺炎的系统评价.中国循证医学杂志,2004,10：693-699.
[18]Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc,2004;60:544-550.
[19]Angelo Andriulli, Rosario Forlano, Grazia Napolitan, et al. Pancreatic duct stents in the prophylaxis of pancreatic d|IImIge after endoscopic retrograde cholangiopancreatography:a systematic analysis of benefits and associated risks. Digestion,2007,75:156-163.
[20]郝立校,龚彪,别里克.胰管支架预防高危ERCP术后胰腺炎的荟萃分析.中华消化内镜杂志,2010,27(2)：94-98.
[21]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc.1991; 37:383-393.
[22]Sherman S, Blaut U, Watkins JL. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis:a randomized, prospective, multicenter study. Gastrointest Endoscop,2003; 58(1):23-29.
[23]刘素丽,张月寒.ERCP术后胰腺炎的研究进展.中国医师进修杂志,2007；30(2)：68-70.
[24]Martin L Freeman. Prevention of post-ERCP pancreatitis:pharmacologic solution or patient selection and pancreatic stents? Gastroenterology.2003; 124(7):1977-1980.
[25]Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction:pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy.2002; 34:280-285.
[26]张姬,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[27]Bakman YG, Safdar K, Freeman ML. Significant clinical implications of prophylactic pancreatic stent placement in previously normal pancreatic ducts. Endoscopy. 2009;41(12):1095-1098.
[1]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158
[2]张亚飞,吴兵,周景丽,等.ERCP治疗急性梗阻性化脓性胆管炎38例.吉林医学,2011；32(1)：2109-2110.
[3]李兆申.ERCP临床应用进展[J].中华消化内镜杂志,2004,21(2)：2231
[4]吴微庆.急性梗阻性化脓性胆管炎的内镜治疗.海南医学院学报,2010；16(7)：907-908.
[5]Moon JH,Cho YD,Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis:comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol,2005; 100:1051-1057
[6]Larkin CJ, Workman A, Wright RE, Tham TC. Radiation doses to patients during ERCP. Gastrointest Endosc,2001; 53:161-164
[7]张姮,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[8]秦明放,赵宏志,王庆,等.微创治疗肝外胆管结石阶梯性方案研究[J].中国实用外 科杂志,2004,24(2)：88-90.
[9]周文策,李玉民,李汛,等.十二指肠镜、腹腔镜和胆道镜联合治疗胆道结石[J].中国内镜杂志,2006；12(6)：590-594.
[10]姚时春,杨俊文,马升高.经内镜胆道支架置入治疗胆道疾病的价值探讨.中国内镜杂志,2008：14(4)：350-353.
[11]胡冰.规范胆管良性狭窄的内镜治疗.中华消化内镜杂志,2009,26(5)：231-233.
[12]宫爱霞,马静,葛林梅,等.内镜治疗肝外胆管良性狭窄29例.世界华人消化杂志,2010,18(9)：950-953
[13]张瑞,贾广志,杨成旺.良性胆道狭窄的金属内支架治疗及其进展[J].内蒙古医学院报,2002,24(4)：286-289.
[14]李兵,曾志武,熊群.经内镜鼻胆管引流治疗术后胆漏.中国内镜杂志,2006,12(11)1188-1189
[15]张啸,张筱风,李国熊,等.内镜治疗术后胆漏和继发胆管狭窄.中华消化内镜杂志2005,22(1)：13-15.
[16]赵秋,覃华,李荣香.ERCP对肝移植术后胆漏诊治作用的前瞻性临床观察.中华消化内镜杂志,2005,22(3)：150-153
[17]Morelli J, Mtdcahy HE, Willner IR, et al. Endoscopic treatment of post-liver transplantation biliary leaks with stent placement across the leak site. Gastrointest Endosc,2001,54:471-475.
[18]丁国乾,秦鸣放,王庆,等.十二指肠镜在诊治腹腔镜胆囊切除术后胆漏中的应用.世界华人消化杂志,2011；19(3)：305-308
[19]陆敏强,蔡常洁,杨扬,等.内镜治疗在肝移植术后胆道并发症中的地位和作用.中国实用外科杂志,2003,23(11).
[20]孙昊,于良,吕毅,等.肝移植术后胆道并发症的内镜治疗.中华消化内镜杂志,2010；27(11)：592-594
[21]李玉民.内镜在肝移植术后胆道并发症中的应用.中国微创外科杂志,2007；7(9)：849-850.
[22]鞠卫强,何晓顺,邰强,等.内镜下逆行胰胆管造影术在肝移植术后胆道并发症中的应用[J].中华临床医师杂志,电子版,2011,5(6)：1597-1600.
[23]朱人敏,张晓华.消化内镜新技术的临床应用进展[J].中华临床医师杂志,电子版,2011,5：944-947.
[24]Claudia Sanna, Chiara Giordanino, Ilaria Giono et al. Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Patients with Post-Liver Transplant Biliary Complications:Results of a Cohort Study with Long-Term Follow-Up. Gut Liver.2011; 5(3):328-334.
[25]沈雪辉,徐美东,姚礼庆,等.内镜治疗胆道蛔虫病的临床价值.中国内镜杂志,2004；10(3)：17-19.
[26]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011：39(2)：381-383.
[27]郝俊鸣,李雪梅,佟艳铭,等.胆道蛔虫病的内镜诊断和治疗体会.中国康复理论与实践,2005,11(12)：1044-1045.
[28]尹凤荣,张涛.原发性硬化性胆管炎12例临床分析.临床肝胆病杂志,2010；26(5)：548-550.
[29]Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis:A single center study. Am J Gastroenterol.2007;102:107-114
[30]Holger H Lutz, Jens JW Tischendorf. Management of primary sclerosing cholangitis. World J Hepatol.2011 27; 3(6):137-141.
[31]Gotthardt DN, Rudolph G, Kloters-Plachky P, et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis:outcome after long-term treatment. Gastrointest Endosc.2010;71:527-534
[32]中华医学会消化内镜分会ERCP学组.内镜下逆行胆胰管造影术(ERCP)诊治指南.(2010版)
[33]邹晓平.ERCP应用指南及进展.第十届国际治疗内镜及消化病学术会议专题报告及论文汇编.2010,06：19-21.
[1]李兆申.胰腺疾病内镜治疗研究进展.中国实用外科杂志,2003；23(1)：31-34.
[2]尹华.内镜治疗胆源性胰腺炎[J].中国中西医结合外科杂志,2007,13(1)：94-96.
[3]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[4]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[5]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004,36:8-16
[6]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志,2007,27：441-443.
[7]周文策,张辉,李汛,等.31例内镜联合早期肠内营养治疗急性重症胆源性胰腺炎.世界华人消化杂志,2009,17(16)：1684-1688
[8]Ji jo V Cherian, Joye Varghese Selvaraj, Rajesh Natrayan and Jayanthi Venkataraman. ERCP in acute pancreatitis. Hepatobiliary Pancreat Dis Int,2007,6:233-240.
[9]李兆申.胰腺疾病的内镜治疗进展：急性胰腺炎内镜治疗的价值及安全性.中国实用外科杂志,2005,25(6)：326-328.
[10]Jacob L, Geenen JE, Catalano MF, Geenen DJ. Prevention of pancreatitis in patients with idiopathic recurrent pancreatitis:a prospective nonblinded randomized study using endoscopic stents. Endoscopy 2001;33:559-562.
[11]麻树人,张宁,赵志峰,等.内镜技术治疗慢性胰腺炎的临床应用价值.解放军医学杂志,2005,30(9)：831-832.
[12]勾承月.胰腺疾病内镜治疗进展.中国中西医结合外科杂志,2007,13(3)：314-315.
[13]李兆申.急、慢性胰腺炎的内镜治疗.肝胆外科杂志,2005,13(3)：167-168.
[14]Van Berkel AM, Cahen DL, Van Wester DJ. et al. Self-expanding metal stents in benign biliary strictures due to chronic pancreatitis[J]. J. Endoscopy,2004, 36:381
[15]郑明伟,秦鸣放,王庆,等.内镜在治疗慢性胰腺炎胰管结石中的应用.中国中西医结合外科杂志,2011,17(1)：27-30.
[16]李兆申,王洛伟,许国铭,等.胰腺分裂症的内镜治疗.解放军医学杂志,2002,27(9)：793-794.
[17]Wehrmann T, Schmitt T, Seifert H. Endoscopic botlinum toxin injection into the minor papilla for treatment of idiopathic recurrent pancreatitis in patients with pancreas divisum. Gantrointest Endosc,1999,50(7):545.
[18]D. Cahen, E. Rauws, P. Fockens, et al. Endoscopic Drainage of Pancreatic Pseudocysts:Long-Term Outcome and Procedural Factors Associated with Safe and Successful Treatment. Endoscopy,2005,37(10):977-983
[19]李兆申.内镜治疗胰腺假性囊肿进展.内科急危重症杂志2003,9(2)：87-92.
[20]林辉.胰腺假性囊肿内镜治疗的临床研究.第二军医大学博士学位论文,2010,05
[21]穆小松,邓明明.胰腺假性囊肿的内镜治疗进展西南军医,2010,12(1)：122-124.
[22]中华医学会消化内镜分会ERCP学组.内镜下逆行胆胰管造影术(ERCP)诊治指南.(2010版)
[23]邹晓平.ERCP应用指南及进展.第十届国际治疗内镜及消化病学术会议专题报告及论文汇编.2010,06：19-21.
[24]郭学刚,邓勇,孙安华,等.假性胰腺囊肿的内镜治疗.中华消化内镜杂志,2003,20(4)：256-259.
[25]李兆申.胰腺疾病的内镜治疗进展.继续医学教育,2007,21(3)：24-26.
[26]李兆申.胰腺疾病的内镜治疗.中华消化杂志,1999,19(3)：152-153.
[27]Coelho DE, Ardengh JC, Carbalo MT, et al. Clinicopathologic characteristics and endoscopic treatment of post-traumatic pancreatic pseudocysts. Pancreas. 2011,40(3):469-473.
[28]Richard A. Erickson. ERCP and Pancreatic Cancer. Annals of Surgical Oncology, 2004,11(6):555-557.
[29]胡冰,周岱云,龚彪,等.1215例次恶性胆管梗阻内镜治疗的体会.中华外科杂志,2001,39(3)：195-198.
[30]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011,39(2)：381-383.
[2]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158.
[3]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[4]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[5]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[6]Gislason H, Horn A, Hoem D, et al. Acute pancreatitis in Bergen, Norway. A study on incidence, etiology and severity. Scand J Surg,2004;93:29-33.
[7]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[8]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志2007；27：441-443
[9]McClave SA, Greene LM, Snider HL, et al. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. JPEN J Parenter Enteral Nutr 1997; 21:14-20
[10]Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol 2006; 20:507-529.
[11]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[12]Freeman ML. DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[13]Christensen M, Matzen P. Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[14]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[15]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[16]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11:222-228.
[17]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656.
[18]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[19]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[20]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[21]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[22]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[23]李汛,朱晓亮,周文策,等.经内镜胰管支架置入在预防ERCP术后胰腺炎高危患者中的临床应用.中国普外基础与临床杂志,2010,17(10)：1006-1009.
[24]潘涛,王一平,杨锦林,等.胰管支架置入术预防内镜逆行胰胆管造影术后胰腺炎的系统评价.中国循证医学杂志,2004,10：693-699.
[25]Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc,2004; 60:544-550.
[26]Angelo Andriulli, Rosario Forlano, Grazia Napolitan, et al. Pancreatic duct stents in the prophylaxis of pancreatic d|IImIge after endoscopic retrograde cholangiopancreatography:a systematic analysis of benefits and associated risks. Digestion,2007,75:156-163.
[27]郝立校,龚彪,别里克.胰管支架预防高危ERCP术后胰腺炎的荟萃分析.中华消化内镜杂志,2010,27(2)：94-98.
[1]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[2]Gislason H, Horn A, Hoem D, et al. Acute pancreatitis in Bergen, Norway. A study on incidence, etiology and severity. Scand J Surg,2004;93:29-33.
[3]张太平,徐徕,赵玉沛.重症急性胰腺炎发病机制.临床外科杂志.2010,18(6)：42]-424.
[4]尹华.内镜治疗胆源性胰腺炎[J].中国中西医结合外科杂志,2007,13(1)：94-96.
[5]Makhija R, Kingsnorth AN.Cytokine storm in acute pancreatitis.J Hepatobiliary Pancreat Surg.2002;9(4):401-10. Review
[6]方金苗,夏时海,李兆申.重症急性胰腺炎发病机制的研究进展.武警医学,2005；16(5)：375-377
[7]张刚,张肇达,刘续宝等.急性胰腺炎大鼠肺内TNF-a基因表达与肺损伤的关系.世界华人消化杂志,2000,8(2)：142
[8]洪亮.急性胰腺炎患者血清CRP、IL-10、TNF-α、NO水平变化及意义.山东医药.2007；47(36)：76-77.
[9]李兆申.胰腺疾病内镜治疗研究进展.中国实用外科杂志,2003；23(1)：31-34.
[10]李兆申.胰腺疾病的内镜治疗进展：急性胰腺炎内镜治疗的价值及安全性.中国实用外科杂志,2005；25(6)：326-328.
[11]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[12]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志,2007；27：441-443.
[13]王文文.血内毒素、D-乳酸、TNF-a在急性胰腺炎发展和转归中的意义.暨南大学硕士学位论文,2011.
[14]中华医学会消化病学分会.肠屏障功能障碍临床诊治建议[J].中华消化杂志,2006,26(9)：620.
[15]寇丽,尤胜义.急性胰腺炎病人T淋巴细胞亚群改变与差异性凋亡.中华肝胆外科杂志.2008,14(8)：569-571
[16]吴阶平,裘法祖.黄家驷外科学.第6版.北京：人民卫生出版社,2005：120-122
[17]都庆国.肠内外营养支持治疗重症急性胰腺炎的临床研究.重庆医科大学硕士论文,2007；03
[18]中华医学会外科学会胰腺学组.急性胰腺炎的临床诊断及分级标准.中华外科杂志1997；35(12)：773-775
[19]邹富胜.急性胆源性胰腺炎的中西医结合治疗.天津医科大学博士学位论文.2006,05
[20]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158
[21]Moon JH, Cho YD, Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis:comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol,2005; 100: 1051-1057
[22]Larkin CJ, Workman A, Wright RE, Tham TC. Radiation doses to patients during ERCP. Gastrointest Endosc,2001; 53:161-164
[23]张姮,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[24]胡冰.规范胆管良性狭窄的内镜治疗.中华消化内镜杂志,2009,26(5)：231-233.
[25]郝俊鸣,李雪梅,佟艳铭,等.胆道蛔虫病的内镜诊断和治疗体会.中国康复理论与实践,2005；11(12)：1044-1045.
[26]沈雪辉,徐美东,姚礼庆,等.内镜治疗胆道蛔虫病的临床价值.中国内镜杂志.2004；10(3)：17-19.
[27]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011；39(2)：381-383.
[28]Sheung-Tat Fan, Edward Lai, Francis Mok, et al. Early treatment of acute biliary pancreatifis by endoscopic papillotomy[J]. N Eng J Med,1993,328:228-232.
[29]罗劲松,张文利,丁顺斌,等.急诊内镜治疗急性胆源性胰腺炎.海南医学,2008；19(9)：42-45.
[30]刘臣海,黄强.内镜治疗51例急性胆源性胰腺炎的临床对比研究.肝胆胰外科杂志,2009；21(1)：56-58.
[31]Cart-Locke DL. Biliary pancreatitis. Can J Gastroenterol,2003; 17(3):205-208.
[32]缪林,范志宁,季国忠,文卫,刘政,黄光明,蒋国斌,吴萍.急性胆源性胰腺炎早期内镜治疗52例.世界华人消化杂志,2004；12：2006-2008.
[33]Jijo V Cherian, Joye Varghese Selvaraj, Rajesh Natrayan and Jayanthi Venkataraman. ERCP in acute pancreatitis. Hepatobiliary Pancreat Dis Int,2007; 6:233-240.
[34]李兆申,许国铭.治疗性ERCP在胰腺疾病中的应用进展.新消化病学杂志,1996；4(5)：277-278
[35]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36:8-16
[36]周鸣清,李能平,陆仁达.急性胆源性胰腺炎的十二指肠镜治疗.中华普通外科杂志2000；15：
[37]王自法,潘承恩,刘绍诰.重症急性胰腺炎发病机理研究进展.中华普通外科杂志1999；14：144-146
[38]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志2007；27：441-443
[39]周文策,张辉,李汛,等.31例内镜联合早期肠内营养治疗急性重症胆源性胰腺炎.世界华人消化杂志,2009；17(16)：1684-1688
[40]Bengmark S. Gut microenvironment and immune function. Curr Opin Clin Nutr Metab Care 1999; 2:83-85
[41]张建松.重症胰腺炎的中西医结合营养支持治疗.北京中医药大学硕士学位论文,2010,05.
[42]Imrie CW, Carter CR, McKay CJ. Enteral and parenteral nutrition in acute pancreatitis. Best Pract Res Clin Gastroenterol 2002; 16:391-397
[43]Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol 2006;20:507-529
[44]Abou-Assi S. Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis:results of a randomized comparative study. Am J Gastroenterol 2002; 97:2255-2262
[45]McClave SA, Snider H, Owens N, Sexton LK. Clinical nutrition in pancreatitis. Dig Dis Sci 1997;42:2035-2044
[46]陈文山,程先能,黄大春.重症急性胰腺炎与免疫应答.检验医学与临床.2009,6(16)：1391-1393.
[47]奚美娟IL.6、IL-10与急性胰腺炎严重程度的相关性研究.苏州大学硕士专业学位论文.2005
[48]陈紫千,汤耀卿.1L-10基因治疗急性胰腺炎的研究现状.国外医学外科学分册,2004,3(1)：74-77
[49]舒国顺.急性胰腺炎早期患者IL-6, TNF, CD4+/CD8+的变化及意义.湖南医学.2000,17(6)：408-410.
[1]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[2]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[3]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[4]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog- raphy. World J Gastroenterol 2007; 13:2655-2668.
[5]Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[6]Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[7]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[8]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[9]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11:222-228.
[10]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656
[11]Lee JK, Park JK, Yoon WJ, et al. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts. J Clin Gastroenterol 2007; 41: 427-431.
[12]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[13]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[14]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc.1991; 37:383-393.
[15]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[16]Pankaj Singh, Ananya Da, Gerard Isenberg, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A metaanalysis of controlled trials. Gastrointest Endosc 2004; 60:544-550.
[17]Akashi R, Kiyozumi T, Tanaka T, et al. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc.2002; 55:50-54.
[18]S. Sherman, T.A. Ruffolo, R.H. Hawes and G.A. Lehman. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology.1991; 101: 1068-1075.
[19]Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media:results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc.1995; 42:312-316.
[20]Baillie J. Predicting and preventing post-ERCP pancreatitis. Curr Gastroenterol Rep.2002; 4:112-119.
[21]Cheung J, Tsoi KK, Quan WL, et al. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis:a systematic review and meta-analysis. Gastrointest Endosc.2009; 70:1211-1219.
[22]Lee TH, Park do H, Park JY, et al. Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. Gastrointest Endosc.2009; 69(3 Pt 1):444-449.
[23]Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc.2004; 59:830-834.
[24]Itoi T, Ishii K, Sofuni A, et al. Single Balloon Enteroscopy-Assisted ERCP Using Rendezvous Technique for Sharp Angulation of Roux-en-Y Limb in a Patient with Bile Duct Stones. Diagn Ther Endosc.2009;2009:154084. Epub 2010 Feb 14.
[25]Martin L Freeman. Prevention of post-ERCP pancreatitis:pharmacologic solution or patient selection and pancreatic stents? Gastroenterology.2003;124(7):1977-1980.
[26]Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction:pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy.2002; 34:280-285.
[27]N Li, A Tieng, S Novak, et al. Effects of Medications on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Pancreatology.2010; 10:238-242
[28]Goulson DT, Fragneto RY. Anesthesia for gastrointestinal endoscopic procedures. Anesthesiol Clin.2009; 27:71-85.
[29]Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation in diagnostic and therapeutic ERCP:propofol is an alternative to midazolam. Endoscopy.2000; 32:233-238.
[30]赵铭宁,杨勇,张文杰,等.ERCP后胰腺炎影响因素分析.肝胆胰外科杂志,2010,22：389-393
[31]潘涛.药物预防ERCP术后胰腺炎的随机对照试验的系统评价.四川大学硕士论文.2004
[1]麻树人.ERCP发展历史回顾与应用现状[J].中国消化内镜杂志,2009.26(5)：225-226.
[2]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[3]李兆申.中国ERCP研究现状[J].中国消化内镜杂志,2008；2(9-10)：1-4.
[4]缪林,范志宁.ERCP并发症防治现状.中国医疗器械信息,2009；15(12)：15-17.
[5]陈震.内镜十二指肠乳头括约肌切开术并发症的临床研究.天津医科大学博士论文.2008
[6]Ayman M Abdel Aziz, Glen A Lehman. Pacreatitis after endoscopic retrograde cholangiopancreatog-raphy. World J Gastroenterol 2007; 13:2655-2668.
[7]Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc.2001; 54:425-434.
[8]Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP:a prospective study. Gastrointest Endosc.2004; 60:721-731.
[9]Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP:a prospective multicenter study. Am JGastroenterol.2001; 96:417-423.
[10]Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol.2006; 101:139-147.
[11]Matsubayashi H, Fukutomi A, Kanemoto H, et al. Risk of pancreatitis after endoscopic retrograde holangiopancreatography and endoscopic biliary drainage. HPB (Oxford).2009; 11: 222-228.
[12]Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc.2002; 56:652-656
[13]Lee JK, Park JK, Yoon WJ, et al. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts. J Clin Gastroenterol 2007; 41: 427-431.
[14]Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP.2002; 3:162-168.
[15]Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol.2009; 104:31-40.
[16]李汛,朱晓亮,周文策,等.经内镜胰管支架置入在预防ERCP术后胰腺炎高危患者中的临床应用.中国普外基础与临床杂志,2010,17(10)：1006-1009.
[17]潘涛,王一平,杨锦林,等.胰管支架置入术预防内镜逆行胰胆管造影术后胰腺炎的系统评价.中国循证医学杂志,2004,10：693-699.
[18]Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc,2004;60:544-550.
[19]Angelo Andriulli, Rosario Forlano, Grazia Napolitan, et al. Pancreatic duct stents in the prophylaxis of pancreatic d|IImIge after endoscopic retrograde cholangiopancreatography:a systematic analysis of benefits and associated risks. Digestion,2007,75:156-163.
[20]郝立校,龚彪,别里克.胰管支架预防高危ERCP术后胰腺炎的荟萃分析.中华消化内镜杂志,2010,27(2)：94-98.
[21]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc.1991; 37:383-393.
[22]Sherman S, Blaut U, Watkins JL. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis:a randomized, prospective, multicenter study. Gastrointest Endoscop,2003; 58(1):23-29.
[23]刘素丽,张月寒.ERCP术后胰腺炎的研究进展.中国医师进修杂志,2007；30(2)：68-70.
[24]Martin L Freeman. Prevention of post-ERCP pancreatitis:pharmacologic solution or patient selection and pancreatic stents? Gastroenterology.2003; 124(7):1977-1980.
[25]Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction:pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy.2002; 34:280-285.
[26]张姬,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[27]Bakman YG, Safdar K, Freeman ML. Significant clinical implications of prophylactic pancreatic stent placement in previously normal pancreatic ducts. Endoscopy. 2009;41(12):1095-1098.
[1]钱东,秦鸣放,王庆,等.十二指肠镜治疗胆总管复发结石440例.世界华人消化杂志2010；18(29)：3155-3158
[2]张亚飞,吴兵,周景丽,等.ERCP治疗急性梗阻性化脓性胆管炎38例.吉林医学,2011；32(1)：2109-2110.
[3]李兆申.ERCP临床应用进展[J].中华消化内镜杂志,2004,21(2)：2231
[4]吴微庆.急性梗阻性化脓性胆管炎的内镜治疗.海南医学院学报,2010；16(7)：907-908.
[5]Moon JH,Cho YD,Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis:comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol,2005; 100:1051-1057
[6]Larkin CJ, Workman A, Wright RE, Tham TC. Radiation doses to patients during ERCP. Gastrointest Endosc,2001; 53:161-164
[7]张姮,黄晓东,吴杰,等.ERCP在胆管良性疾病治疗中的作用.华中科技大学学报(医学版),2009,3(3)：368-370.
[8]秦明放,赵宏志,王庆,等.微创治疗肝外胆管结石阶梯性方案研究[J].中国实用外 科杂志,2004,24(2)：88-90.
[9]周文策,李玉民,李汛,等.十二指肠镜、腹腔镜和胆道镜联合治疗胆道结石[J].中国内镜杂志,2006；12(6)：590-594.
[10]姚时春,杨俊文,马升高.经内镜胆道支架置入治疗胆道疾病的价值探讨.中国内镜杂志,2008：14(4)：350-353.
[11]胡冰.规范胆管良性狭窄的内镜治疗.中华消化内镜杂志,2009,26(5)：231-233.
[12]宫爱霞,马静,葛林梅,等.内镜治疗肝外胆管良性狭窄29例.世界华人消化杂志,2010,18(9)：950-953
[13]张瑞,贾广志,杨成旺.良性胆道狭窄的金属内支架治疗及其进展[J].内蒙古医学院报,2002,24(4)：286-289.
[14]李兵,曾志武,熊群.经内镜鼻胆管引流治疗术后胆漏.中国内镜杂志,2006,12(11)1188-1189
[15]张啸,张筱风,李国熊,等.内镜治疗术后胆漏和继发胆管狭窄.中华消化内镜杂志2005,22(1)：13-15.
[16]赵秋,覃华,李荣香.ERCP对肝移植术后胆漏诊治作用的前瞻性临床观察.中华消化内镜杂志,2005,22(3)：150-153
[17]Morelli J, Mtdcahy HE, Willner IR, et al. Endoscopic treatment of post-liver transplantation biliary leaks with stent placement across the leak site. Gastrointest Endosc,2001,54:471-475.
[18]丁国乾,秦鸣放,王庆,等.十二指肠镜在诊治腹腔镜胆囊切除术后胆漏中的应用.世界华人消化杂志,2011；19(3)：305-308
[19]陆敏强,蔡常洁,杨扬,等.内镜治疗在肝移植术后胆道并发症中的地位和作用.中国实用外科杂志,2003,23(11).
[20]孙昊,于良,吕毅,等.肝移植术后胆道并发症的内镜治疗.中华消化内镜杂志,2010；27(11)：592-594
[21]李玉民.内镜在肝移植术后胆道并发症中的应用.中国微创外科杂志,2007；7(9)：849-850.
[22]鞠卫强,何晓顺,邰强,等.内镜下逆行胰胆管造影术在肝移植术后胆道并发症中的应用[J].中华临床医师杂志,电子版,2011,5(6)：1597-1600.
[23]朱人敏,张晓华.消化内镜新技术的临床应用进展[J].中华临床医师杂志,电子版,2011,5：944-947.
[24]Claudia Sanna, Chiara Giordanino, Ilaria Giono et al. Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Patients with Post-Liver Transplant Biliary Complications:Results of a Cohort Study with Long-Term Follow-Up. Gut Liver.2011; 5(3):328-334.
[25]沈雪辉,徐美东,姚礼庆,等.内镜治疗胆道蛔虫病的临床价值.中国内镜杂志,2004；10(3)：17-19.
[26]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011：39(2)：381-383.
[27]郝俊鸣,李雪梅,佟艳铭,等.胆道蛔虫病的内镜诊断和治疗体会.中国康复理论与实践,2005,11(12)：1044-1045.
[28]尹凤荣,张涛.原发性硬化性胆管炎12例临床分析.临床肝胆病杂志,2010；26(5)：548-550.
[29]Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis:A single center study. Am J Gastroenterol.2007;102:107-114
[30]Holger H Lutz, Jens JW Tischendorf. Management of primary sclerosing cholangitis. World J Hepatol.2011 27; 3(6):137-141.
[31]Gotthardt DN, Rudolph G, Kloters-Plachky P, et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis:outcome after long-term treatment. Gastrointest Endosc.2010;71:527-534
[32]中华医学会消化内镜分会ERCP学组.内镜下逆行胆胰管造影术(ERCP)诊治指南.(2010版)
[33]邹晓平.ERCP应用指南及进展.第十届国际治疗内镜及消化病学术会议专题报告及论文汇编.2010,06：19-21.
[1]李兆申.胰腺疾病内镜治疗研究进展.中国实用外科杂志,2003；23(1)：31-34.
[2]尹华.内镜治疗胆源性胰腺炎[J].中国中西医结合外科杂志,2007,13(1)：94-96.
[3]陈其奎.急性胰腺炎的病因和发病机制[J].现代消化及介入诊疗,2007,12(3)：160-162.
[4]李兆申.中国ERCP研究现状[J].世界华人消化杂志,2000；8(4)：446-448.
[5]Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004,36:8-16
[6]胡兵,陈平,唐承薇.内镜联合药物治疗急性重症胰腺炎153例临床分析.中国实用内科杂志,2007,27：441-443.
[7]周文策,张辉,李汛,等.31例内镜联合早期肠内营养治疗急性重症胆源性胰腺炎.世界华人消化杂志,2009,17(16)：1684-1688
[8]Ji jo V Cherian, Joye Varghese Selvaraj, Rajesh Natrayan and Jayanthi Venkataraman. ERCP in acute pancreatitis. Hepatobiliary Pancreat Dis Int,2007,6:233-240.
[9]李兆申.胰腺疾病的内镜治疗进展：急性胰腺炎内镜治疗的价值及安全性.中国实用外科杂志,2005,25(6)：326-328.
[10]Jacob L, Geenen JE, Catalano MF, Geenen DJ. Prevention of pancreatitis in patients with idiopathic recurrent pancreatitis:a prospective nonblinded randomized study using endoscopic stents. Endoscopy 2001;33:559-562.
[11]麻树人,张宁,赵志峰,等.内镜技术治疗慢性胰腺炎的临床应用价值.解放军医学杂志,2005,30(9)：831-832.
[12]勾承月.胰腺疾病内镜治疗进展.中国中西医结合外科杂志,2007,13(3)：314-315.
[13]李兆申.急、慢性胰腺炎的内镜治疗.肝胆外科杂志,2005,13(3)：167-168.
[14]Van Berkel AM, Cahen DL, Van Wester DJ. et al. Self-expanding metal stents in benign biliary strictures due to chronic pancreatitis[J]. J. Endoscopy,2004, 36:381
[15]郑明伟,秦鸣放,王庆,等.内镜在治疗慢性胰腺炎胰管结石中的应用.中国中西医结合外科杂志,2011,17(1)：27-30.
[16]李兆申,王洛伟,许国铭,等.胰腺分裂症的内镜治疗.解放军医学杂志,2002,27(9)：793-794.
[17]Wehrmann T, Schmitt T, Seifert H. Endoscopic botlinum toxin injection into the minor papilla for treatment of idiopathic recurrent pancreatitis in patients with pancreas divisum. Gantrointest Endosc,1999,50(7):545.
[18]D. Cahen, E. Rauws, P. Fockens, et al. Endoscopic Drainage of Pancreatic Pseudocysts:Long-Term Outcome and Procedural Factors Associated with Safe and Successful Treatment. Endoscopy,2005,37(10):977-983
[19]李兆申.内镜治疗胰腺假性囊肿进展.内科急危重症杂志2003,9(2)：87-92.
[20]林辉.胰腺假性囊肿内镜治疗的临床研究.第二军医大学博士学位论文,2010,05
[21]穆小松,邓明明.胰腺假性囊肿的内镜治疗进展西南军医,2010,12(1)：122-124.
[22]中华医学会消化内镜分会ERCP学组.内镜下逆行胆胰管造影术(ERCP)诊治指南.(2010版)
[23]邹晓平.ERCP应用指南及进展.第十届国际治疗内镜及消化病学术会议专题报告及论文汇编.2010,06：19-21.
[24]郭学刚,邓勇,孙安华,等.假性胰腺囊肿的内镜治疗.中华消化内镜杂志,2003,20(4)：256-259.
[25]李兆申.胰腺疾病的内镜治疗进展.继续医学教育,2007,21(3)：24-26.
[26]李兆申.胰腺疾病的内镜治疗.中华消化杂志,1999,19(3)：152-153.
[27]Coelho DE, Ardengh JC, Carbalo MT, et al. Clinicopathologic characteristics and endoscopic treatment of post-traumatic pancreatic pseudocysts. Pancreas. 2011,40(3):469-473.
[28]Richard A. Erickson. ERCP and Pancreatic Cancer. Annals of Surgical Oncology, 2004,11(6):555-557.
[29]胡冰,周岱云,龚彪,等.1215例次恶性胆管梗阻内镜治疗的体会.中华外科杂志,2001,39(3)：195-198.
[30]周梅花,赵亚刚.ERCP在胆胰疾病中的应用现状.临床军医杂志,2011,39(2)：381-383.